Vanda Pharmaceuticals (VNDA) Prepaid Assets (2010 - 2026)
Vanda Pharmaceuticals (VNDA) posted Prepaid Assets of $32.3 million for Q1 2026, up 19.63% sequentially from $27.0 million in Q4 2025, and up 57.65% YoY from $20.5 million in Q1 2025.
Analysis
Vanda Pharmaceuticals (VNDA) Prepaid Assets (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals has reported Prepaid Assets for 17 years, with the latest figure at $32.3 million in Q1 2026.
- Quarterly Prepaid Assets rose 57.65% year-over-year to $32.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.3 million (up 57.65% YoY) and the FY2025 annual result came in at $27.0 million, up 75.0% from the prior year.
- Prepaid Assets advanced to $32.3 million in Q1 2026 per VNDA's latest filing, from $27.0 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $32.3 million in Q1 2026 and troughed at $6.6 million in Q1 2023.
- A 5-year average of $17.5 million and a median of $17.7 million in 2022 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2023 and 2025: Prepaid Assets sank 73.95% in 2023, then jumped 189.82% in 2025.
- Over 5 years, Prepaid Assets stood at $17.7 million in 2022, then slumped by 48.27% to $9.2 million in 2023, then soared by 68.16% to $15.4 million in 2024, then jumped by 75.0% to $27.0 million in 2025, then increased by 19.63% to $32.3 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $32.3 million, $27.0 million, and $21.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Vanda Pharmaceuticals | 327.03 Mn | 157.00 Mn | 46.97 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 33.09 Mn |
| Mar 31, 2026 | 32.28 Mn |
| Dec 31, 2025 | 26.99 Mn |
| Sep 30, 2025 | 21.16 Mn |
| Jun 30, 2025 | 22.21 Mn |
| Mar 31, 2025 | 20.48 Mn |
| Dec 31, 2024 | 15.42 Mn |
| Sep 30, 2024 | 11.76 Mn |
| Jun 30, 2024 | 8.17 Mn |
| Mar 31, 2024 | 7.07 Mn |
| Dec 31, 2023 | 9.17 Mn |
| Sep 30, 2023 | 16.44 Mn |
| Jun 30, 2023 | 9.45 Mn |
| Mar 31, 2023 | 6.59 Mn |
| Dec 31, 2022 | 17.73 Mn |
| Sep 30, 2022 | 21.37 Mn |
| Jun 30, 2022 | 25.74 Mn |
| Mar 31, 2022 | 25.31 Mn |
| Dec 31, 2021 | 12.00 Mn |
| Sep 30, 2021 | 13.44 Mn |